US Stock MarketDetailed Quotes

VERU Veru Inc

Watchlist
  • 0.700
  • +0.054+8.27%
Close Mar 28 16:00 ET
  • 0.690
  • -0.010-1.44%
Post 19:56 ET
102.48MMarket Cap-636P/E (TTM)

About Veru Inc Company

Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 clinical trial of enobosarm for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The company was founded by William R. Gargiulo, Jr., O. B. Parrish, and Harry Fisch in 1971 and is headquartered in Miami, FL.

Company Profile

SymbolVERU
Company NameVeru Inc
Listing Date07/01/1990
Issue Price6.00
Founded1971
CEODr. Mitchell S. Steiner, F.A.C.S.,M.D.
MarketNASDAQ
Employees189
Securities TypeOrdinary Shares
Fiscal Year Ends09-30
Address2916 North Miami Avenue,Suite 1000
CityMiami
ProvinceFlorida
CountryUnited States of America
Zip Code33127
Phone1-305-509-6897

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Mitchell S. Steiner, F.A.C.S.,M.D.
  • Chairman of the Board, President and Chief Executive Officer
  • 4.71M
  • K. Gary Barnette, PhD
  • Chief Scientific Officer
  • 1.69M
  • Michele Greco
  • Principal Accounting Officer, Chief Financial Officer and Chief Administrative Officer
  • 1.55M
  • Dr. Harry Fisch, M.D.
  • Vice Chairman of the Board and Chief Corporate Officer
  • 816.93K
  • Michael L. Rankowitz
  • Independent Director
  • 875.93K
  • Dr. Lucy Lu, M.D.
  • Independent Director
  • 835.75K
  • Dr. Mario Eisenberger, M.D.
  • Independent Director
  • 795.57K
  • Grace S. Hyun, M.D.
  • Independent Director
  • 755.39K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg